The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Open accessAbstract
This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant Enterobacteriaceae (CRE). Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public health threat. Carbapenems have been used as the “last-line” treatment for infections caused by resistant Enterobacteriaceae, including those producing extended spectrum ß-lactamases. However, Enterobacteriaceae that produce carbapenemases, which are enzymes that deactivate carbapenems and most other ß-lactam antibiotics, have emerged and are increasingly being reported worldwide. Despite this increasing burden, the most optimal treatment for CRE infections is largely unknown. For the few remaining available treatment options, there are limited efficacy data to support their role in therapy. Nevertheless, current treatment options include the use of older agents, such as polymyxins, fosfomycin, and aminoglycosides, which have been rarely used due to efficacy and/or toxicity concerns. Optimization of dosing regimens and combination therapy are additional treatment strategies being explored. Carbapenem-resistant Enterobacteriaceae infections are associated with poor outcomes and high mortality. Continued research is critically needed to determine the most appropriate treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, P., Dortet, L., & Poirel, L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.003 · Cited by 1,038
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 531
Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
Cited by
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Van, T. T. H., Yidana, Z., Smooker, P. M., & Coloe, P. J. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.07.031 · Cited by 451
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Wu, J. Y., Srinivas, P., & Pogue, J. M. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00286-6 · Cited by 195
Self-citationManohar, P., Shanthini, T., Ayyanar, R., Bozdogan, B., Wilson, A., Tamhankar, A. J., Nachimuthu, R., & Lopes, B. S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000508 · Cited by 104
D’Accolti, M., Soffritti, I., Bini, F., Mazziga, E., Mazzacane, S., & Caselli, E. (2022) · Microorganisms · doi:10.3390/microorganisms10020225 · Cited by 39
Kumudunie, W. G. M., Wijesooriya, L. I., Namalie, K. D., Sunil-Chandra, N. P., & Wijayasinghe, Y. S. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.04.010 · Cited by 21
Metadata
- Authors
- Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015
- Volume
- 2
- Issue
- 2
- Pages
- ofv050-ofv050
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W2112203749
- Cited by
- 435
- References
- 67
- FWCI
- 16.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. https://app.cochat.ai/papers/10.1093/ofid/ofv050
- The paper
- Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015). Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofv050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
